Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Avalon Pharmaceuticals has nominated AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program.
Subscribe to our email newsletter
This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The company plans to begin clinical testing of AVN316 in patients in 2009.
Using AvalonRx, the company identified several chemical compound series that inhibit beta-catenin function. One family of structurally distinct chemical compounds potently down-regulate the Beta-catenin pathway by reducing beta-catenin protein levels
Beta-catenin is said to be the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer.
Kenneth Carter, president and CEO of Avalon, said: “We are very pleased to name AVN316 as the lead compound for this intractable target, which we believe provides validation for our unique drug discovery platform, AvalonRx.”